SEAGEN INC. Inactive Instrument
Funds and ETFs Seagen Inc.
Equities
SGEN
US81181C1045
Biotechnology & Medical Research
ETFs positioned on Seagen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.99% | 254 M€ | +11.50% | - | |
| 2.68% | 1 M€ | -2.17% | - | |
| 2.53% | 0 M€ | 0.00% | - | |
| 2.25% | 0 M€ | 0.00% | - | |
| 1.75% | 4 M€ | +20.15% | ||
| 1.58% | 9 M€ | -4.31% | - | |
| 1.00% | 1,100 M€ | +2.94% | ||
| 0.95% | 8 M€ | +4.88% | ||
| 0.85% | 85 M€ | +0.69% | ||
| 0.61% | 17 M€ | +6.60% | - | |
| 0.30% | 9 M€ | -.--% | - | |
| 0.24% | 15 M€ | 0.00% | - | |
| 0.22% | 3 M€ | 0.00% | - | |
| 0.17% | 50 M€ | +9.42% | ||
| 0.14% | 330 M€ | -.--% | ||
| 0.12% | 368 M€ | +18.65% | - | |
| 0.10% | 375 M€ | +8.48% | ||
| 0.08% | 1,487 M€ | +7.21% | - | |
| 0.08% | 34 M€ | +11.93% | - | |
| 0.08% | 9 M€ | +9.18% | - | |
| 0.07% | 744 M€ | +8.90% |
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit :
- ventes de produits (87%) ;
- royalties (8,4%) ;
- revenus issus d'accords de collaboration et de licence (4,6%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +22.78% | 44.96B | |
| +1.13% | 42.65B | |
| +45.83% | 41.85B | |
| -4.27% | 29.04B | |
| +11.18% | 26.08B | |
| -21.29% | 19.03B | |
| +6.60% | 12.75B | |
| +28.48% | 12.06B | |
| -4.26% | 11.75B |
